The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Phase II study of burixafor + propranolol + G-CSF for stem cell mobilization in myeloma
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, discusses the results of an open-label, multi-center Phase II study (NCT05561751) assessing the safety and efficacy of burixafor and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma. The study found 90% of patients achieved the primary endpoint of collecting at least 2 million cells for infusion in two apheresis sessions, with 85% of patients who received daratumumab and lenalidomide for induction achieving this endpoint. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
